Dana-Farber researchers find link between multiple doses of COVID-19 vaccine and cancer patient outcomes

Boston-based Dana-Farber Cancer Institute researchers found multiple doses of the COVID-19 vaccine reduced mortality and negative health outcomes in breakthrough cases for cancer patients.

Advertisement
By: Mariah Taylor

The study, published Feb. 13 in The Lancet Regional Health, analyzed 2,486 patients with laboratory-confirmed COVID-19 in 2021 or 2022. Of those patients, 564 had two doses of an mRNA vaccine and 385 had three doses. 

Here are three findings:

  1. Patients with two or three doses had better outcomes, including decreased 30-day mortality, hospitalization and ICU admissions.
  2. Black patients had higher rates of hospitalization.
  3. Hispanic patients had higher rates of ICU admission.
Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.